文献速递泌尿男性生殖肿瘤消化系统肿瘤

肾细胞癌胃肠道转移:一项回顾性多中心GETUG研究

Gastrointestinal metastases in renal cell carcinoma: A retrospective multicenter GETUG (Groupe d'Étude des Tumeurs Uro-Génitales) study.
PubMed 文献 · Eur J Cancer · 2024-01-15

该回顾性多中心研究纳入2000至2021年法国10个GETUG中心的74例肾细胞癌胃肠道转移患者,共87处胃肠道转移灶,多为胃或十二指肠。胃肠道转移诊断后中位总生存期为19个月。作者认为,有肾细胞癌病史的患者出现贫血或消化道出血时应怀疑胃肠道转移。

要点

  • 肾细胞癌胃肠道转移罕见,诊断后中位总生存期19个月。
  • 70%的胃肠道转移有症状,其中贫血55%、消化道出血42%。
  • 仅30%的无症状患者为偶然诊断,有肾癌史者出现贫血或消化道出血应怀疑。

核心结论

  • 作者报告了目前最大规模的肾细胞癌胃肠道转移回顾性队列,认为有肾细胞癌病史的患者出现贫血或消化道出血时应怀疑胃肠道转移。

研究设计与样本

  • 回顾性多中心研究,收集2000年至2021年法国10个GETUG中心中表现为胃肠道转移的肾细胞癌患者数据。

主要发现

  • 共识别74例患者、87处胃肠道转移,大多为胃或十二指肠。
  • 胃肠道转移诊断时中位年龄69岁,76%的患者已存在其他转移。
  • 胃肠道转移距肾细胞癌诊断的中位时间为5.4年(95%CI=[4.2-7.1]),距首次转移的中位时间为1.9年(95%CI=[1.2-3.8])。
  • 52例(70%)胃肠道转移有症状,其中贫血41例(55%)、消化道出血31例(42%);仅22例(30%)无症状患者为偶然诊断。
  • 诊断胃肠道转移后中位总生存期为19个月。

关键数值与推荐

  • 87处胃肠道转移中,29处(33%)仅接受全身治疗,23处(26%)仅接受局部治疗,18处(21%)接受局部联合全身治疗,17处(20%)未进行治疗调整。

临床怎么用

  • 作者认为,有肾细胞癌病史的患者出现贫血或消化道出血时应怀疑胃肠道转移。
  • 胃肠道转移的管理因消化道部位及是否有症状而差异很大。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Among patients with renal cell carcinoma (RCC), bone and visceral metastases have a poor prognosis, while endocrine gland metastases have a more favorable prognosis. Gastrointestinal metastases (GIMs) are rare, and their prognosis is still poorly understood. OBJECTIVES: To report clinical presentations, patient characteristics, therapeutic strategies, and prognosis of GIMs from RCC. METHODS: We retrospectively collected data from RCC patients presenting GIMs, in 10 French GETUG centers, between 2000 and 2021. RESULTS: We identified 74 patients with 87 GIMs, mostly gastric or duodenal. The median age at GIM diagnosis was 69 years and 76% of patients already had other metastases. GIMs occurred after a median duration of 5.4 years (IC95%=[4.2-7.1]) and 1.9 years (IC95%=[1.2-3.8]) from RCC diagnosis and first metastasis, respectively. GIMs were symptomatic in 52 patients (70%), with anemia in 41 patients (55%) and/or gastrointestinal bleeding in 31 patients (42%). Only 22 asymptomatic patients (30%) were fortuitously diagnosed. GIM management consisted of systemic treatment only in 29 GIMs (33%), local treatment only in 23 GIMs (26%), and both local and systemic treatment in 18 GIMs (21%). For 17 GIMs (20%), there was no therapeutic modification. After diagnosis of GIM, median overall survival was 19 months. CONCLUSION: We report the largest retrospective cohort of GIMs in RCC patients. They should be suspected in case of anemia or gastrointestinal bleeding in any patient with a history of RCC. Their management varies widely depending on their location in the digestive tract and whether or not they are symptomatic.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Carneiro F, Vinceneux A, Larroquette M, et al. Gastrointestinal metastases in renal cell carcinoma: A retrospective multicenter GETUG (Groupe d'Étude des Tumeurs Uro-Génitales) study. Eur J Cancer. 2024. PMID: 38241819. doi:10.1016/j.ejca.2024.113534

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。